Enliven Therapeutics, Inc. (ELVN)
(Real Time Quote from BATS)
$24.04 USD
-0.45 (-1.84%)
Updated May 14, 2024 02:52 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
ELVN 24.04 -0.45(-1.84%)
Will ELVN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ELVN
3 Stocks in the Limelight on New Analyst Coverage
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELVN
Commit To Purchase Enliven Therapeutics At $10, Earn 11.2% Annualized Using Options
Buy Rating Affirmed: Enliven Therapeutics’ ELVN-001 Shows Market Potential and Efficacy in Resistant Patients
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
Enliven Therapeutics files to sell 6.43M shares for holders
Enliven files to sell 6.43M shares of common stock for holders